A new study shows a bone drug could reduce the risk of breast cancer in women under the age of 50.
Breast cancer specialist and researcher Dr. Qamar Khan with the KU Medical Center said during an Australian trial, the drug, Zometa, or Zoledronic acid, actually reduced the risk of breast cancer in women.
According to Khan, the drug also improved a woman's chances of survival.
"I think it's potentially practice changing. That some women with breast cancer who are less than 50 years of age, may live longer just because of this medication, by a huge magnitude. The chances of living longer are about 35 percent more,” said Khan.
Khan said Zometa also has fewer side effects than chemotherapy.
Copyright 2011 Scripps Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
In the most prominent challenge of its kind, Hobby Lobby Stores Incorporated has asked a federal appeals court for an exemption from part of the federal health care law.